December Approvals Forecast: FDA Decisions Will Be Fast And Frequent
This article was originally published in The Pink Sheet Daily
Executive Summary
Another record-breaking year of approvals seems almost certain given the number of products with user fee goals before the end of 2015.
You may also be interested in...
HCV Forecast: Merck, AbbVie Next-Gen Data Not Overtaking Gilead
Gilead's ASTRAL study data at AASLD represent a "shock-and-awe" campaign, setting up the company for continued HCV dominance over several competitors, Wall Street analyst asserts.
Minimal Residual Disease Gains Max US FDA AdComm Support For Myeloma Trials
The US FDA’s Oncologic Drugs Advisory Committee unanimously agreed that accelerated approvals should be enabled by multiple myeloma trials using MRD as a surrogate endpoint.
Minimal Residual Disease Inches Closer To Supporting Myeloma Accelerated Approvals
US FDA’s oncology advisory committee will discuss two meta-analyses supporting use of MRD as a surrogate endpoint to support accelerated approval in multiple myeloma trials.